Network meta‐analysis (NMA) is essential for clinical decision‐making. NMA enables
inference for all pair‐wise comparisons between interventions available for the same …

Multiple randomized controlled trials, each comparing a subset of competing interventions,
can be synthesized by means of a network meta‐analysis to estimate relative treatment …

Multiple randomized controlled trials, each comparing a subset of competing interventions,
can be synthesized by means of a network meta-analysis to estimate relative treatment …

Network meta-analysis (NMA) combines direct and indirect evidence from trials to calculate
and rank treatment effect estimates. While modelling approaches for continuous and binary …

Randomised controlled trials of cancer treatments typically report progression free survival
(PFS) and overall survival (OS) outcomes. Existing methods to synthesise evidence on PFS …

Network meta‐analysis (NMA) allows the combination of direct and indirect evidence from a
set of randomized clinical trials. Performing NMA using individual patient data (IPD) is …

Aim: Technical Support Document 21 discusses trial-based, flexible relative survival models.
The authors generalized flexible relative survival models to the network meta-analysis …

Background Data on survival endpoints are usually summarised using either hazard ratio,
cumulative number of events, or median survival statistics. Network meta-analysis, an …

Fits Bayesian time-course models for model-based network meta-analysis (MBNMA) that
allows inclusion of multiple time-points from studies. Repeated measures over time are …

Network meta-analysis combines aggregate data (AgD) from multiple randomised controlled
trials, assuming that any effect modifiers are balanced across populations. Individual patient …